Presented by LabRoots

Cardiovascular disease is a leading health problem, affecting almost 30% of individuals in the developed world, and comprises a wide range of disorders from acute heart failure to congenital heart abnormalities. While complex genetic mechanisms are thought to underlie many types of heart disorders, the lack of reliable model systems that recapitulate heart development and disease is hampering the mechanistic understanding and dissection of disease phenotypes. With the capability to differentiate into any type of body cell, pluripotent stem cells (PSCs) have emerged as a powerful tool to study human development and disease biology.

Join this webinar to understand how robust PSC-based platforms and tools are being used to study cardiovascular development, maturation, and disease phenotypes. These technologies include microfluidics-based sorting of cardiomyocytes, single-cell transcriptomics and in vitro functional assays to model cardiac development using cardiac progenitor cells. The development of new PSC-based targeted therapies aimed at treating cardiac diseases will also be discussed.

In this webinar, you will also:

  • Outline how PSCs differentiate into cells of different lineages and their use in modeling development and disease
  • Review single-cell analysis techniques employed for isolation and analysis of cardiac progenitor cells used for modeling heart development and disease
  • Examine in vivo maturation systems for iPSC-based modeling of cardiomyopathy


Who should attend

This webinar will provide insights to researchers who want to learn about how PSCs can be used to study cardiac development and disease.



Dr. Peter Andersen
Assistant Professor and Group Leader, Johns Hopkins University School of Medicine, and Co-founder, Vita Therapeutics

Dr. Andersen's specialties include cell therapy, gene therapy, gene-editing, heart development and disease, cancer biology, genetic and molecular diagnostics, drug discovery, pharmacology, pluripotent stem cells and 3D cell engineering. His previous positions include Executive Board Member, Johns Hopkins Biotech Investment Group (JHBIG) and Founder JHU Stem Cell Consortium. He received his PhD from the University of Copenhagen.